Gert W. Munthe, Chairman

Munthe is the second largest shareholder in Lytix Biopharma and the Chairman and Founding Partner of Herkules Capital, an Oslo-based, Nordic, mid-market PE firm. As former CEO of Nycomed Imaging he oversaw the development, launch and marketing of three imaging products that all reached blockbuster sales. Nycomed Imaging was acquired by GE Healthcare. As Chairman of Pronova in 2004-2013 Munthe monitored the regulatory approval of and market launch of Omacor/Lovaza which through licensees reached blockbuster sales. Pronova was acquired by BASF.

Marie-Louise Fjällskog, MD, PhD

Dr. Fjällskog is a Senior Life Science Executive with a long track-record within Clinical Research and Development, mainly Immuno-oncology. She is a Board Member of Biovica International AB, Sweden, and serves as Chief Medical Officer in Faron Pharmaceuticals Ltd, Turku, Finland / Boston, a clinical stage biopharmaceutical company focused on cancer and inflammation. Previous to Faron Pharmaceuticals, she was CMO in Sensei Biotherapeutics. Dr. Fjällskog holds a PhD in oncology and is an Associate Professor (docent) of Oncology, affiliated to Uppsala University, Sweden. Earlier she worked as a medical oncologist with more than 25 years of clinical experience.

Brynjar Forbergskog

Brynjar Forbergskog is the CEO of his privately owned investment company, in addition to being a board member of several companies. From 1989 to 2019 he was the CFO (1989-2005) and CEO (2005-2019) of Torghatten ASA. During Forbergskog' s tenure as CFO/CEO, Torghatten ASA grew from being a small locally based provider of transport services into being of the Nordics' largest providers of transport services, with more than 7000 employees and an annual turnover of more than NOK 11 billion. Prior to joining Torghatten ASA, Brynjar Forbergskog was an external auditor.

Kjetil Hestdal, MD, PhD

Dr. Hestdal is a Senior Life Science Executive, who previously among others held the position as CEO of Photocure ASA, a commercial-stage company focused on bladder cancer and listed on the Oslo Stock Exchange. Presently he is a board member and provides consulting services related to development and commercial expertise to pharma, medtech and biotech companies. Dr Hestdal holds a Ph.D. in immunology.

Jayson Rieger, PhD, MBA

Jayson has about 15 years experience in cross-functional scientific and business leadership roles spanning business, research operations, drug discovery and product development in the life science. He presently serves as Managing Partner in PBM Capital and supports new investment evaluation, deal sourcing and provides business and technical support for portfolio companies. Jayson obtained his Ph.D. from the University of Virginia in Chemistry, has an MBA from the Darden Business School and earned his B.A. from Rollins College.

Evelina Vågesjö, PhD, MBA

Dr. Vågesjö is co-founder and CEO of Ilya Pharma AB, a company developing next generation immunotherapies based on cutting edge medical research in immunophysiology and applied microbiology. She has received numerous awards within Science and Innovation, among these, she was one of the winners of Innovators Under 35 Europe from MIT Technology Review 2019 and was featured on the Global PowerList 2021 by the Medicine Maker. Dr. Vågesjö holds a Ph.D. in Physiology from Uppsala University and a MBA from Heriot-Watt University, Edinburgh.